Differences in drug resistance of HIV-1 genotypes in CSF and plasma and analysis of related factors

Jie Wang, Mei Li, Jungang Li, Renni DengVirulence 2023 · DOI

TL;DR

This study reveals that HIV drug resistance mutations found in cerebrospinal fluid (CSF) are consistent with those in plasma, suggesting a shared evolutionary path. Crucially, it identifies antiretroviral (ARV) treatment as a significant factor increasing the likelihood of drug resistance developing within the central nervous system (CNS) reservoir.

What Problem Does This Paper Address?

While antiretroviral therapy (ART) has dramatically improved outcomes for people living with HIV (PLWH), the emergence of drug resistance remains a significant challenge, impacting treatment efficacy and patient quality of life. A particular concern is HIV's ability to establish reservoirs within the central nervous system (CNS), protected by the blood-brain barrier. This CNS reservoir can evolve independently, leading to "viral escape" and treatment failure, yet research on drug resistance specifically within CSF has been limited. This paper aims to bridge this gap by comparing HIV drug resistance in CSF and plasma and identifying factors that contribute to resistance in the CNS.

Methods

The researchers analyzed matched CSF and plasma samples from 62 HIV-1 patients in Chongqing, China, between 2019 and 2022. HIV genotyping and drug resistance mutations were determined using the Stanford HIV Drug Resistance Database v8.7 algorithm. Clinical data, including diagnosis and treatment information, were collected from patient records. Statistical analysis, including one-way and multivariate ANOVA, was employed to identify factors associated with drug resistance mutations in CSF.

Datasets

The study utilized retrospective clinical data and biological samples (CSF and plasma) from 62 HIV-1 patients. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • CSF and Plasma Mirror Each Other: The finding that HIV drug resistance mutations in CSF are consistent with those in plasma is significant. It suggests that the virus's evolution towards resistance is not entirely compartmentalized within the CNS and that resistance observed in plasma may reflect or predict resistance in the CNS.
  • ARV Treatment as a Driver of CNS Resistance: The most striking insight is the strong association between receiving ARV treatment and the development of drug resistance in CSF. This challenges the notion that ART solely suppresses viral replication everywhere and highlights the complex interplay between drug penetration, viral reservoirs, and treatment.
  • INSTIs Show Promise (So Far): The absence of integrase strand transfer inhibitor (INSTI) resistance mutations in this cohort is noteworthy, especially given INSTIs are among the newer ARV classes with higher genetic barriers to resistance. This suggests they may be a more robust option for preventing resistance, at least in the short term.

Key Results

  • Out of 62 patients, 13 (21.0%) showed drug-resistant mutations.
  • The most common HIV-1 subtype was CRF07-BC (64.5%).
  • Resistance mutation sites were consistent between CSF and plasma samples.
  • The prevalence of drug-resistant mutations was significantly higher in patients receiving ARV treatment (8/11, 72.7%) compared to untreated patients (5/51, 9.8%).
  • Multivariate analysis confirmed that ARV treatment was a significant factor associated with CSF resistance (P < 0.001).
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) showed the highest mutation frequency, while no INSTI mutations were detected.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The study included a relatively small sample size (62 patients), which may limit the generalizability of the findings.
  • Limited Detection: Six patients had low CSF viral loads, preventing drug resistance testing, and the study's detection methods might not capture all subtle resistance patterns.
  • Cross-Sectional Design: The study is cross-sectional, making it difficult to establish definitive causal relationships.
  • Further Exploration Needed: The authors suggest that future research should aim to detect deeper underlying correlations between CSF resistance and influencing factors, explore other relevant factors, and investigate the impact of specific ARV regimens on CSF resistance. They also highlight the need for further studies on the penetration of ARV drugs into the CNS and the role of adherence.

Summary updated

Abstract

The emergence of HIV drug resistance seriously affects the quality of life of patients. However, there has been no extensive study of CSF resistance. The aim of this study is to evaluate common HIV-1 resistance in CSF and compare it with resistance in matched plasma, and analyse the influencing factors of cerebrospinal fluid drug resistance. The matched CSF and plasma samples of 62 HIV-1 patients were tested at one study site in China (Chongqing; 2019-2022). HIV genotyping and drug resistance was evaluated using the Stanford v8.7 algorithm. The diagnosis and treatment data and basic information were collected from the clinical case system, and the influencing factors of drug resistance mutations in CSF was obtained by variance analysis. CSF and matched plasma HIV-1 subtypes were confirmed in 62 patients, and the most frequent recombinant form was CRF07-BC (64.5%). Thirteen patients (21.0%) were detected with drug-resistant mutations, and the sites were consistent in both CSF and matched plasma. The drug-resistant ratios of untreated patients and treated patients were 5/51 (9.8%) and 8/11 (72.7%), respectively. The type with the highest mutation frequency was NNRTI, and no mutation was found in INSTI. Multivariate analysis indicated that ARV treatment was associated with CSF resistance (<i>P</i> < 0.001). The subtypes and drug resistance mutation sites are consistent in CSF and matched plasma samples of HIV-1 patients, and there is a correlation between ARV treatment and possible drug resistance, especially in CSF reservoirs. These findings highlight the concern about CSF drug resistance in HIV patients.
BibTeX
@inproceedings{wang2023differences,
  author = {Jie Wang and Mei Li and Jungang Li and Renni Deng},
  title = {{Differences in drug resistance of HIV-1 genotypes in CSF and plasma and analysis of related factors}},
  booktitle = {Virulence},
  year = {2023},
  doi = {10.1080/21505594.2023.2171632},
}
Figure